The OJC Episode 7: ASCO 2024 Special Part 2
Send us a text Discover the latest breakthroughs from ASCO 2024 with The Oncology Journal Club team! Professor Chris Jackson, who, despite battling the infamous man flu, brings his A-game to dissect the NADINA study. Learn how neoadjuvant ipilimumab and nivolumab are transforming resectable stage 3 melanoma treatment with a remarkable 26 percentage point gain in 12-month event-free survival. Chris shines a spotlight on the innovative design of this trial and its promising implications for re...